Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty
Ключови думи
Резюме
Описание
Total knee replacement is an effective method to treat end-stage osteoarthritis. However, post-operative pain is still a bothering problem. Pre-emptive analgesia is defined as an antinociceptive treatment which prevents pain before its onset. Preoperative analgesia is thought more effective than an equal post-operative dose. Surgical trauma induces the synthesis of prostaglandins, which sensitize the peripheral nociceptors.Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit prostaglandin synthesis both in the periphery and the spinal cord, therefore decreasing the post-operative hyperalgesic state.
Celebrex (Celecoxib) is a nonsteroidal anti-inflammatory drug (NSAID) that is used to treat arthritis, pain, menstrual cramps, and colonic polyps. Prostaglandins are chemicals that are important contributors to the inflammation of arthritis that causes the pain, fever, swelling and tenderness. Celecoxib blocks the enzyme that makes prostaglandins (cyclooxygenase 2), resulting in lower concentrations of prostaglandins. As a consequence, inflammation and its accompanying pain, fever, swelling and tenderness are reduced. Celecoxib differs from other NSAIDs in that it causes less inflammation and ulceration of the stomach and intestine (at least with short-term treatment) and does not interfere with the clotting of blood.
The study group received 400mg oral celecoxib about 1 hr prior to total knee replacement surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients had spinal anesthesia and hemovac drain tubes inserted for postoperative blood loss evaluation.
Specific aims and goals:
1. to establish better rehabilitation results and lower VAS pain scores after administration perioperative celecoxib in total knee replacement patients.
2. to establish morphine sparing effect after perioperative celecoxib administration.
3. to evaluate the risks after prescribing perioperative celecoxib.
Дати
| Последна проверка: | 05/31/2010 |
| Първо изпратено: | 01/09/2008 |
| Очаквано записване подадено: | 01/09/2008 |
| Първо публикувано: | 01/20/2008 |
| Изпратена последна актуализация: | 06/19/2010 |
| Последна актуализация публикувана: | 06/21/2010 |
| Действителна начална дата на проучването: | 08/31/2006 |
| Приблизителна дата на първично завършване: | 07/31/2009 |
| Очаквана дата на завършване на проучването: | 07/31/2009 |
Състояние или заболяване
Интервенция / лечение
Drug: Celecoxib (Celebrex)
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Active Comparator: 1 Celecoxib (Celebrex) | |
| Placebo Comparator: 2 Placebo |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 60 Years Да се 60 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: - Patients receiving total knee replacement will be recruited in this study. Exclusion Criteria: - subjects with end-stage renal disease, cerebral vascular accident, peptic ulcer, long-term usage of NSAIDs. |
Резултат
Първични изходни мерки
1. VAS pain scores, range-of-motion, narcotics usage [post-op 6hrs,12hrs,day1,day2,day3,day7]
